IL145447A0 - Composition for the preservation of infectious recombinant adenoviruses - Google Patents

Composition for the preservation of infectious recombinant adenoviruses

Info

Publication number
IL145447A0
IL145447A0 IL14544700A IL14544700A IL145447A0 IL 145447 A0 IL145447 A0 IL 145447A0 IL 14544700 A IL14544700 A IL 14544700A IL 14544700 A IL14544700 A IL 14544700A IL 145447 A0 IL145447 A0 IL 145447A0
Authority
IL
Israel
Prior art keywords
preservation
composition
recombinant adenoviruses
infectious recombinant
infectious
Prior art date
Application number
IL14544700A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9904443A external-priority patent/FR2791999B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL145447A0 publication Critical patent/IL145447A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14544700A 1999-04-09 2000-04-07 Composition for the preservation of infectious recombinant adenoviruses IL145447A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9904443A FR2791999B1 (fr) 1999-04-09 1999-04-09 Composition destinee a la conservation d'adenovirus recombinants infectieux
US13212099P 1999-04-30 1999-04-30
PCT/FR2000/000879 WO2000061726A1 (fr) 1999-04-09 2000-04-07 Composition destinee a la conservation d'adenovirus recombinants infectieux

Publications (1)

Publication Number Publication Date
IL145447A0 true IL145447A0 (en) 2002-06-30

Family

ID=26234910

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14544700A IL145447A0 (en) 1999-04-09 2000-04-07 Composition for the preservation of infectious recombinant adenoviruses
IL145447A IL145447A (en) 1999-04-09 2001-09-13 Preparation for the preservation of contagious recombinant adenoviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL145447A IL145447A (en) 1999-04-09 2001-09-13 Preparation for the preservation of contagious recombinant adenoviruses

Country Status (17)

Country Link
US (2) US6734008B2 (fr)
EP (1) EP1194529A1 (fr)
JP (1) JP2002541792A (fr)
KR (1) KR20020013521A (fr)
CN (1) CN1347450A (fr)
AU (1) AU778894B2 (fr)
BR (1) BR0009595A (fr)
CA (1) CA2364562A1 (fr)
CZ (1) CZ20013560A3 (fr)
HK (1) HK1045716A1 (fr)
HU (1) HUP0200821A3 (fr)
IL (2) IL145447A0 (fr)
MX (1) MXPA01010124A (fr)
NO (1) NO20014765D0 (fr)
NZ (1) NZ514731A (fr)
PL (1) PL351553A1 (fr)
WO (1) WO2000061726A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009595A (pt) * 1999-04-09 2001-12-26 Aventis Pharma Sa Composição lìquida ou congelada e utilizaçãoterapêutica ou profilática da mesma
PL199642B1 (pl) * 2002-11-15 2008-10-31 Inst Immunologii I Terapii Do Preparat bakteriofagowy o podwyższonej trwałości oraz zastosowanie blokowego kopolimeru tlenku etylenu i tlenku propylenu
WO2005052116A2 (fr) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preparations de virus contenant un conservateur
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
CN103173493B (zh) * 2009-09-29 2014-09-24 成都康弘生物科技有限公司 一种含有重组腺病毒的制剂
CN103173494B (zh) * 2009-09-29 2015-02-18 成都康弘生物科技有限公司 一种含有重组腺病毒的制剂
CN102031246B (zh) * 2009-09-29 2013-09-11 成都康弘生物科技有限公司 一种含有重组腺病毒的制剂
RS57043B1 (sr) 2013-10-25 2018-05-31 Psioxus Therapeutics Ltd Onkolitički adenovirusi snabdeveni heterologus genima
KR101845715B1 (ko) * 2015-06-03 2018-04-05 (주)제노텍 동결방지제 조성물
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
ES2938833T3 (es) * 2016-03-28 2023-04-17 Ultragenyx Pharmaceutical Inc Métodos de inactivación térmica de adenovirus
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
CN110938603B (zh) * 2019-12-20 2022-11-22 阿吉安(福州)基因医学检验实验室有限公司 一种通用型病毒样本保存缓冲液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831919B1 (fr) * 1995-05-16 2002-10-16 TRYGGVASON, Karl Procede d'administration de produits pharmaceutiques par therapie genetique
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
BR0009595A (pt) * 1999-04-09 2001-12-26 Aventis Pharma Sa Composição lìquida ou congelada e utilizaçãoterapêutica ou profilática da mesma

Also Published As

Publication number Publication date
JP2002541792A (ja) 2002-12-10
CZ20013560A3 (cs) 2002-01-16
CN1347450A (zh) 2002-05-01
AU778894B2 (en) 2004-12-23
BR0009595A (pt) 2001-12-26
KR20020013521A (ko) 2002-02-20
NO20014765L (no) 2001-10-01
EP1194529A1 (fr) 2002-04-10
PL351553A1 (en) 2003-05-05
US7202078B2 (en) 2007-04-10
US20040191909A1 (en) 2004-09-30
NZ514731A (en) 2004-03-26
HUP0200821A2 (hu) 2002-07-29
HK1045716A1 (zh) 2002-12-06
IL145447A (en) 2006-10-05
CA2364562A1 (fr) 2000-10-19
MXPA01010124A (es) 2002-06-26
WO2000061726A1 (fr) 2000-10-19
NO20014765D0 (no) 2001-10-01
AU3825500A (en) 2000-11-14
HUP0200821A3 (en) 2004-11-29
US20020061592A1 (en) 2002-05-23
US6734008B2 (en) 2004-05-11

Similar Documents

Publication Publication Date Title
EP1453536A4 (fr) Composition pour la conservation de virus
HUP0103908A3 (en) Novel infulenza virus vaccine composition
HUP0203056A3 (en) Vaccine composition
PL343065A1 (en) Vaccine composition
AU3808700A (en) Compositions and methods for recombinant adeno-associated virus production
HUP0200821A3 (en) Composition for the preservation of infectious recombinant adenoviruses
GB9902520D0 (en) Composition
GB9801870D0 (en) Vaccine composition
EP1246635A4 (fr) Peptides designes superfamille o- de conotoxines
GB9925709D0 (en) Composition
GB2366984B (en) Composition
GB9914446D0 (en) Composition
ZA200108224B (en) Composition for the prevention of infectious recombinant adenoviruses.
IL132665A0 (en) Anti viral composition
AU1316201A (en) Polypeptide composition
IL128742A0 (en) Recombinant adenovirus vector
GB9906694D0 (en) Vaccine composition
GB9906696D0 (en) Vaccine composition
GB9802879D0 (en) Vaccine composition
GB9806455D0 (en) Vaccine composition
GB9806525D0 (en) Recombinant virus
GB9914596D0 (en) Composition
GB9925711D0 (en) Composition
GB9907270D0 (en) Composition
GB9914710D0 (en) Composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed